Additionally, the drug reduced severe side effects like heart damage compared to a standard doxorubicin-based treatment.
“We are excited by these results demonstrating that pixantrone is living up to the promise of preventing the severe cardiac damage that accompanies the use of standard doxorubicin treatment while retaining the potent anti-lymphoma activity of this class of drug,” said James Bianco, president and CEO of CTI.
“Pending results from this and other studies, these findings could have major implications for treating patients with breast cancer, lymphoma, and leukemia, where debilitating cardiac damage from doxorubicin might be prevented,” he added.
The company is planning to report the trial’s results in December.